Broad phenotypic changes associated with gain of radiation resistance in head and neck squamous cell cancer

Antioxidants and Redox Signaling

Volumn 21, Issue 2, 2014, Pages 221-236

  Bansal, Nidhi ^a   Mims, Jade ^a   Kuremsky, Jeffrey G ^a   Olex, Amy L ^b   Zhao, Weiling ^a   Yin, Leimiao ^a   Wani, Revati ^a   Qian, Jiang ^a   Center, Brian ^a   Marrs, Glen S ^b   Porosnicu, Mercedes ^a   Fetrow, Jacquelyn S ^b   Tsang, Allen W ^a   Furdui, Cristina M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN; ERLOTINIB; FATTY ACID SYNTHASE; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; VASCULOTROPIN; EPIDERMAL GROWTH FACTOR RECEPTOR; QUINAZOLINE DERIVATIVE;

ACTIN FILAMENT; CANCER RADIOTHERAPY; CANCER RADIOTHERAPY RESISTANCE; CELL INTERACTION; CONCENTRATION RESPONSE; DNA DAMAGE; DNA REPLICATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EXCISION REPAIR; EXTRACELLULAR MATRIX; FOCAL ADHESION; G2 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; MASS SPECTROMETRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEOMICS; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; THERAPY RESISTANCE; UPREGULATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; DRUG EFFECTS; GENETICS; HEAD AND NECK NEOPLASMS; IONIZING RADIATION; METABOLISM; PHOSPHORYLATION; RADIATION DOSE; RADIATION RESPONSE; TUMOR CELL CULTURE;

CARCINOMA, SQUAMOUS CELL; ERLOTINIB HYDROCHLORIDE; HEAD AND NECK NEOPLASMS; HUMANS; PHENOTYPE; PHOSPHORYLATION; QUINAZOLINES; RADIATION TOLERANCE; RADIATION, IONIZING; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 84902469041     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5690     Document Type: Review

References (53)

1. Aitken A and Learmonth M. Protein identification by in-gel digestion and mass spectrometric analysis. Mol Biotechnol 20: 95-97, 2002 (Pubitemid 34113577)
2. Anderson JM, Heindl LM, Bauman PA, Ludi CW, Dalton WS, and Cress AE. Cytokeratin expression results in a drug-resistant phenotype to six different chemotherapeutic agents. Clin Cancer Res 2: 97-105, 1996 (Pubitemid 26042184)
3. Avila-Campillo I, Drew K, Lin J, Reiss DJ, and Bonneau R. BioNetBuilder: automatic integration of biological networks. Bioinformatics 23: 392-393, 2007 (Pubitemid 46323169)
4. Bandyopadhyay S, Zhan R, Wang Y, Pai SK, Hirota S, Hosobe S, Takano Y, Saito K, Furuta E, Iiizumi M, Mohinta S, Watabe M, Chalfant C, and Watabe K. Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res 66: 5934-5940, 2006 (Pubitemid 43927149)
5. Basu D, Montone KT, Wang LP, Gimotty PA, Hammond R, Diehl JA, Rustgi AK, Lee JT, Rasanen K, Weinstein GS, and Herlyn M. Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle 10: 2008-2016, 2011
6. Benavente S, Huang S, Armstrong EA, Chi A, Hsu KT, Wheeler DL, and Harari PM. Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. Clin Cancer Res 15: 1585-1592, 2009
7. Bendall SC, Hughes C, Stewart MH, Doble B, Bhatia M, and Lajoie GA. Prevention of amino acid conversion in SILAC experiments with embryonic stem cells. Mol Cell Proteomics 7: 1587-1597, 2008
8. Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, Trott KR, and Wilson GD. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 23: 5560-5567, 2005
9. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, and Ang KK. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med 354: 567-578, 2006 (Pubitemid 43209104)
10. Bump EA and Brown JM. Role of glutathione in the radiation response of mammalian cells in vitro and in vivo. Pharmacol Ther 47: 117-136, 1990 (Pubitemid 20183311)
11. Cappuzzo F. Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? J Natl Cancer Institute 97: 868-869, 2005 (Pubitemid 41417931)
12. Caulin C, Ware CF, Magin TM, and Oshima RG. Keratindependent, epithelial resistance to tumor necrosis factorinduced apoptosis. J Cell Biol 149: 17-22, 2000 (Pubitemid 30196695)
13. Chong CR and Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19: 1389- 1400, 2013
14. Christian AE, Haynes MP, Phillips MC, and Rothblat GH. Use of cyclodextrins for manipulating cellular cholesterol content. J Lipid Res 38: 2264-2272, 1997 (Pubitemid 27495385)
15. Crissman JD, Pajak TF, Zarbo RJ, Marcial VA, and Al- Sarraf M. Improved response and survival to combined cisplatin and radiation in non-keratinizing squamous cell carcinomas of the head and neck. An RTOG study of 114 advanced stage tumors. Cancer 59: 1391-1397, 1987 (Pubitemid 17044991)
16. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA, Jr., and Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 6: 1683-1691, 2007 (Pubitemid 46954044)
17. Gee JM and Nicholson RI. Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res 5: 126-129, 2003 (Pubitemid 36519404)
18. Gupta SC, Hevia D, Patchva S, Park B, Koh W, and Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 16: 1295-1322, 2012
19. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA, Jelluma N, Arvold ND, Baumber R, Lamborn KR, Kapadia A, Malec M, Berger MS, and Stokoe D. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97: 880-887, 2005 (Pubitemid 41417939)
20. Harari PM and Huang S. Radiation combined with EGFR signal inhibitors: head and neck cancer focus. Semin Radiat Oncol 16: 38-44, 2006 (Pubitemid 41832314)
21. Hirschhaeuser F, Sattler UG, and Mueller-Klieser W. Lactate: A metabolic key player in cancer. Cancer Res 71: 6921-6925, 2011
22. Hong KO, Kim JH, Hong JS, Yoon HJ, Lee JI, Hong SP, and Hong SD. Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells. J Exp Clin Cancer Res 28: 28, 2009
23. Huang da W, Sherman BT, and Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13, 2009
24. Huang da W, Sherman BT, and Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57, 2009
25. Irwin ME, Mueller KL, Bohin N, Ge Y, and Boerner JL. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 226: 2316-2328, 2011
26. Jemal A, Siegel R, Ward E, Murray T, Xu J, and Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 57: 43-66, 2007
27. Kanda R, Kawahara A, Watari K, Murakami Y, Sonoda K, Maeda M, Fujita H, Kage M, Uramoto H, Costa C, Kuwano M, and Ono M. Erlotinib resistance in lung cancer cells mediated by integrin beta1/Src/Akt-driven bypass signaling. Cancer Res 73: 6243-6253, 2013
28. Kanehisa M and Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28: 27-30, 2000 (Pubitemid 30047706)
29. Kao YC, Lee SW, Lin LC, Chen LT, Hsing CH, Hsu HP, Huang HY, Shiue YL, Chen TJ, and Li CF. Fatty acid synthase overexpression confers an independent prognosticator and associates with radiation resistance in nasopharyngeal carcinoma. Tumour Biol 34: 759-768, 2013
30. Khodarev NN, Beckett M, Labay E, Darga T, Roizman B, and Weichselbaum RR. STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. Proc Natl Acad Sci U S A 101: 1714-1719, 2004 (Pubitemid 38234220)
31. Klymkowsky MW and Savagner P. Epithelial-mesenchymal transition: A cancer researcher's conceptual friend and foe. Am J Pathol 174: 1588-1593, 2009
32. Lee YS, Chang HW, Jeong JE, Lee SW, and Kim SY. Proteomic analysis of two head and neck cancer cell lines presenting different radiation sensitivity. Acta Otolaryngol 128: 86-92, 2008
33. Li B, Zhang C, He F, Liu W, Yang Y, Liu H, Liu X, Wang J, Zhang L, Deng B, Gao F, Cui J, Liu C, and Cai J. GSK- 3beta Inhibition Attenuates LPS-Induced Death but Aggravates Radiation-Induced Death via Down-Regulation of IL-6. Cell Physiol Biochem 32: 1720-1728, 2013
34. Liu H, Liu Y, and Zhang JT. A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression- mediated palmitate overproduction. Mol Cancer Ther 7: 263-270, 2008 (Pubitemid 351302520)
35. Lu SP, Lin Feng MH, Huang HL, Huang YC, Tsou WI, and Lai MZ. Reactive oxygen species promote raft formation in T lymphocytes. Free Radic Biol Med 42: 936-944, 2007
36. Marcial VA, Pajak TF, Mohiuddin M, Cooper JS, al Sarraf M, Mowry PA, Curran W, Crissman J, Rodriguez M, and Velez-Garcia E. Concomitant cisplatin chemotherapy and radiotherapy in advanced mucosal squamous cell carcinoma of the head and neck. Long-term results of the Radiation Therapy Oncology Group study 81-17. Cancer 66: 1861-1868, 1990 (Pubitemid 20385952)
37. Mitchell JB and Russo A. The role of glutathione in radiation and drug induced cytotoxicity. Br J Cancer Suppl 8: 96-104, 1987 (Pubitemid 17108366)
38. Morgan MJ, Kim YS, and Liu Z. Lipid rafts and oxidative stress-induced cell death. Antioxid Redox Signal 9: 1471-1483, 2007 (Pubitemid 47255027)
39. Nijkamp MM, Span PN, Hoogsteen IJ, van der Kogel AJ, Kaanders JH, and Bussink J. Expression of E-cadherin and vimentin correlates with metastasis formation in head and neck squamous cell carcinoma patients. Radiother Oncol 99: 344-348, 2011
40. Ong SE and Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc 1: 2650-2660, 2006
41. Park SH, Chung YM, Lee YS, Kim HJ, Kim JS, Chae HZ, and Yoo YD. Antisense of human peroxiredoxin II enhances radiation-induced cell death. Clin Cancer Res 6: 4915-4920, 2000
42. Parkins CS, Stratford MR, Dennis MF, Stubbs M, and Chaplin DJ. The relationship between extracellular lactate and tumour pH in a murine tumour model of ischaemiareperfusion. Br J Cancer 75: 319-323, 1997 (Pubitemid 27051044)
43. Prasad TS, Kandasamy K, and Pandey A. Human Protein Reference Database and Human Proteinpedia as discovery tools for systems biology. Methods Mol Biol 577: 67-79, 2009
44. Qian J, Klomsiri C, Wright MW, King SB, Tsang AW, Poole LB, and Furdui CM. Simple synthesis of 1,3-cyclopentanedione derived probes for labeling sulfenic acid proteins. Chem Commun 47: 9203-9205, 2011
45. Quiet CA, Weichselbaum RR, and Grdina DJ. Variation in radiation sensitivity during the cell cycle of two human squamous cell carcinomas. Int J Radiat Oncol Biol Phys 20: 733-738, 1991
46. Ramsamooj P, Kasid U, and Dritschilo A. Differential expression of proteins in radioresistant and radiosensitive human squamous carcinoma cells. J Natl Cancer Inst 84: 622-628, 1992
47. Smoot ME, Ono K, Ruscheinski J, Wang PL, and Ideker T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27: 431-432, 2011
48. Thomas GJ, Lewis MP, Whawell SA, Russell A, Sheppard D, Hart IR, Speight PM, and Marshall JF. Expression of the alphavbeta6 integrin promotes migration and invasion in squamous carcinoma cells. J Invest Dermatol 117: 67-73, 2001 (Pubitemid 32652441)
49. Tilghman RW, Slack-Davis JK, Sergina N, Martin KH, Iwanicki M, Hershey ED, Beggs HE, Reichardt LF, and Parsons JT. Focal adhesion kinase is required for the spatial organization of the leading edge in migrating cells. J Cell Sci 118: 2613-2623, 2005 (Pubitemid 40932887)
50. Ushio-Fukai M. Localizing NADPH oxidase-derived ROS. Sci STKE 2006: re8, 2006
51. Weichselbaum RR, Beckett MA, Vijayakumar S, Simon MA, Awan AM, Nachman J, Panje WR, Goldman ME, Tybor AG, Moran WJ, et al. Radiobiological characterization of head and neck and sarcoma cells derived from patients prior to radiotherapy. Int J Radiat Oncol Biol Phys 19: 313-319, 1990 (Pubitemid 20299023)
52. Weichselbaum RR, Dahlberg W, Beckett M, Karrison T, Miller D, Clark J, and Ervin TJ. Radiation-resistant and repair-proficient human tumor cells may be associated with radiotherapy failure in head- and neck-cancer patients. Proc Natl Acad Sci U S A 83: 2684-2688, 1986 (Pubitemid 16026948)
53. Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider M, Fan Q, Schmidt CM, Chiorean EG, Xie J, Cheng L, Chen JH, and Zhang JT. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol 2: 89-98, 2011.